/VTYX
VTYX Stock - Ventyx Biosciences, Inc.
Healthcare|BiotechnologyNASDAQ
$8.74+12.92%
+$1.00 (+12.92%) • Dec 19
84
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.BUY
High Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.100
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).100
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.71
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+83.1%upside
Target: $16.00
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for VTYX
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$8.65 – $8.83
TARGET (TP)$16.00
STOP LOSS$8.04
RISK/REWARD1:10.4
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta1.23
52W High$10.55
52W Low$0.78
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | N/A | N/A | N/A | N/A | N/A |
| Gross Margin | N/A | N/A | N/A | N/A | N/A |
| Operating Income | $-148,450,000 | $-207,994,000 | $-113,136,000 | $-67,147,000 | $-7,050,000 |
| Net Income | $-135,122,000 | $-192,962,000 | $-108,426,000 | $-83,746,000 | $-28,174,000 |
| Net Margin | N/A | N/A | N/A | N/A | N/A |
| EPS | $-1.97 | $-3.30 | $-2.06 | $-1.69 | $-0.56 |
Company Overview
Ventyx Biosciences, Inc., a clinical-stage biopharmaceutical company, develops small molecule product candidates for inflammatory diseases and autoimmune disorders. The company's lead product candidate is VTX958, a tyrosine kinase type 2 inhibitor that is in phase I clinical trials for the treatment of immune-mediated diseases, such as psoriasis, inflammatory bowel disease, psoriatic arthritis, Crohn's disease, and lupus. It also develops VTX002, an oral sphingosine 1 phosphate receptor 1 modulator that is in phase II clinical trials for the treatment of ulcerative colitis; and VTX2735, a peripheral-targeted NOD-like receptor protein 3 (NLRP3) inflammasome inhibitor for the treatment of systemic inflammatory diseases, such as cardiovascular, hepatic, renal, and rheumatologic diseases which is in phase I clinical trials. In addition, the company develops CNS-penetrant NLRP3 inhibitors for the treatment of Alzheimer disease, Parkinson disease, amyotrophic lateral sclerosis, and multiple sclerosis. Ventyx Biosciences, Inc. was incorporated in 2018 and is based in Encinitas, California.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
7
64%
Hold / Neutral
4
36%
Sell / Underperform
0%
Analyst Consensus🟡 Mixed
7 Bullish4 Neutral/Bearish
Price Targets
$33
Average Target
↑ 282.9% Upside
Now
$6
Low
$33
Average
$77
High
Based on 13 analysts
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| November 5th 2025 | H.C. Wainwright | Upgrade | Buy | $18 |
| March 12th 2024 | Oppenheimer | Upgrade | Outperform | $12 |
| March 12th 2024 | Wells Fargo | Upgrade | Overweight | $16← $7 |
| November 7th 2023 | Morgan Stanley | Downgrade | Equal Weight | $6← $46 |
| November 7th 2023 | Oppenheimer | Downgrade | Perform | - |
| November 7th 2023 | H.C. Wainwright | Downgrade | Neutral | - |
| November 7th 2023 | Stifel | Downgrade | Hold | $6 |
| November 7th 2023 | Wells Fargo | Downgrade | Equal Weight | $8← $77 |
| June 14th 2023 | Credit Suisse | Resumed | Outperform | $63 |
| March 21st 2023 | Wells Fargo | Initiation | Overweight | $77 |
| December 19th 2022 | Goldman | Initiation | Buy | $50 |
| November 17th 2022 | Morgan Stanley | Initiation | Overweight | $45 |
| September 7th 2022 | Stifel | Initiation | Buy | $45 |
| September 1st 2022 | H.C. Wainwright | Initiation | Buy | $36 |
| May 9th 2022 | Credit Suisse | Initiation | Outperform | $53 |
Earnings History & Surprises
VTYXBeat Rate
47%
Last 17 quarters
Avg Surprise
-40.6%
EPS vs Estimate
Beats / Misses
8/9
Last 12 quarters
Latest EPS
$-0.32
Q4 2025
EPS Surprise History
Q1 24
-1.3%
$-0.79vs$-0.78
Q2 24
+7.5%
$-0.62vs$-0.67
Q3 24
+21.1%
$-0.45vs$-0.57
Q4 24
-4.2%
$-0.50vs$-0.48
Q1 25
+24.1%
$-0.41vs$-0.54
Q2 25
+18.7%
$-0.39vs$-0.48
Q3 25
+15.6%
$-0.38vs$-0.45
Q4 25
+28.9%
$-0.32vs$-0.45
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q1 2026 | Feb 26, 2026 | $-0.41 | — | — | — |
Q4 2025 | Nov 6, 2025 | $-0.45 | $-0.32 | +28.9% | ✓ BEAT |
Q3 2025 | Aug 7, 2025 | $-0.45 | $-0.38 | +15.6% | ✓ BEAT |
Q2 2025 | May 8, 2025 | $-0.48 | $-0.39 | +18.7% | ✓ BEAT |
Q1 2025 | Feb 27, 2025 | $-0.54 | $-0.41 | +24.1% | ✓ BEAT |
Q4 2024 | Nov 7, 2024 | $-0.48 | $-0.50 | -4.2% | ✗ MISS |
Q3 2024 | Aug 8, 2024 | $-0.57 | $-0.45 | +21.1% | ✓ BEAT |
Q2 2024 | May 9, 2024 | $-0.67 | $-0.62 | +7.5% | ✓ BEAT |
Q1 2024 | Feb 27, 2024 | $-0.78 | $-0.79 | -1.3% | ✗ MISS |
Q4 2023 | Nov 9, 2023 | $-0.85 | $-0.92 | -8.2% | ✗ MISS |
Q3 2023 | Aug 10, 2023 | $-0.71 | $-0.91 | -28.2% | ✗ MISS |
Q2 2023 | May 11, 2023 | $-0.64 | $-0.68 | -6.3% | ✗ MISS |
Q1 2023 | Mar 23, 2023 | $-0.59 | $-0.62 | -5.1% | ✗ MISS |
Q4 2022 | Nov 3, 2022 | $-0.45 | $-0.59 | -31.1% | ✗ MISS |
Q3 2022 | Aug 15, 2022 | $-0.47 | $-0.39 | +17.0% | ✓ BEAT |
Q2 2022 | May 12, 2022 | $-0.37 | $-0.45 | -21.6% | ✗ MISS |
Q1 2022 | Mar 23, 2022 | $-1.00 | $-0.36 | +64.0% | ✓ BEAT |
Q4 2021 | Nov 17, 2021 | $-0.36 | $-3.17 | -780.6% | ✗ MISS |
Q4 2021 | Oct 21, 2021 | — | $-0.74 | — | — |
Q1 2021 | Mar 31, 2021 | — | $-1.78 | — | — |
Latest News
Ventyx Pushes Heart Drug Trial Results to 2026 to Test New "Once-Daily" Pill, Taps Heavyweight Advisors, Including CEO Behind $11B Merck Deal
➖ NeutralBenzinga•Dec 2, 2025, 12:07 PM•Also:
Canaccord Genuity Maintains Buy on Ventyx Biosciences, Raises Price Target to $16
📈 PositiveBenzinga•Nov 7, 2025, 10:13 PM•Also:
Wells Fargo Maintains Overweight on Ventyx Biosciences, Raises Price Target to $14
📈 PositiveBenzinga•Nov 7, 2025, 06:45 PM
Ventyx Biosciences Q3 EPS $(0.32) Beats $(0.45) Estimate
📈 PositiveBenzinga•Nov 6, 2025, 09:43 PM
HC Wainwright & Co. Upgrades Ventyx Biosciences to Buy, Announces $18 Price Target
📈 PositiveBenzinga•Nov 5, 2025, 11:24 AM
Oppenheimer Maintains Outperform on Ventyx Biosciences, Raises Price Target to $14
📈 PositiveBenzinga•Oct 27, 2025, 12:54 PM
Ventyx Biosciences shares are trading higher after the company announced results from its Phase 2 study of VTX3232 in participants with obesity and cardiovascular risk factors.
📈 PositiveBenzinga•Oct 23, 2025, 03:10 PM
Ventyx surges on mid-stage trial data for heart disease drug
📈 PositiveSeeking Alpha•Oct 23, 2025, 11:53 AM
Ventyx Biosciences shares are trading higher after the company announced results from its Phase 2 study of VTX3232 in participants with obesity and cardiovascular risk factors.
📈 PositiveBenzinga•Oct 22, 2025, 08:47 PM
Ventyx Biosciences Announces Positive Results From Phase 2 Trial Of VTX3232 For Obesity, Cardiovascular Risk Factors; Vtx3232 Monotherapy Achieved ~80% Reduction In Hscrp; Vtx3232 Monotherapy Reduced Il-6 Levels
📈 PositiveBenzinga•Oct 22, 2025, 08:05 PM
Ventyx Biosciences shares are trading higher after Clear Street initiated coverage on the stock with a Buy rating and announced a $11 price target.
📈 PositiveBenzinga•Oct 1, 2025, 04:52 PM
Clear Street Initiates Coverage On Ventyx Biosciences with Buy Rating, Announces Price Target of $11
📈 PositiveBenzinga•Oct 1, 2025, 12:57 PM
Frequently Asked Questions about VTYX
What is VTYX's current stock price?
Ventyx Biosciences, Inc. (VTYX) is currently trading at $8.74 per share. The stock has moved +12.92% today.
What is the analyst price target for VTYX?
The average analyst price target for VTYX is $16.00, based on 1 analyst.
What sector is Ventyx Biosciences, Inc. in?
Ventyx Biosciences, Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is VTYX's market cap?
Ventyx Biosciences, Inc. has a market capitalization of $0.62 billion, making it a small-cap company.
Does VTYX pay dividends?
No, Ventyx Biosciences, Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorABSI
Absci Corporation
$3.38
Mkt Cap: $0.5B
CRVS
Corvus Pharmaceuticals, Inc.
$7.49
Mkt Cap: $0.6B
GOSS
Gossamer Bio, Inc.
$3.44
Mkt Cap: $0.8B
KALV
KalVista Pharmaceuticals, Inc.
$15.23
Mkt Cap: $0.8B
MLTX
MoonLake Immunotherapeutics
$13.39
Mkt Cap: $0.9B
OLMA
Olema Pharmaceuticals, Inc.
$27.93
Mkt Cap: $1.9B
PRTA
Prothena Corporation plc
$9.21
Mkt Cap: $0.5B
RGNX
REGENXBIO Inc.
$14.59
Mkt Cap: $0.7B
RIGL
Rigel Pharmaceuticals, Inc.
$41.59
Mkt Cap: $0.7B
VSTM
Verastem, Inc.
$7.76
Mkt Cap: $0.5B
Explore stocks similar to VTYX for comparison